Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | ACACB | O00763 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23051836 | 1.00 | LDHA (0.62) | LDHASLC6A4ACACBALDH1A1PPARG | |
| SCHEMBL27795435 | 0.87 | LDHA (0.65) | LDHASLC6A4ACACBALDH1A1PPARG | |
| SCHEMBL9293068 | 0.86 | ESR1 (0.48) | — | |
| SCHEMBL663059 | 0.85 | LDHA (0.73) | LDHASLC6A4ACACBPPARGPPARA | |
| SCHEMBL8283100 | 0.85 | LDHA (0.73) | LDHASLC6A4ACACBPPARGPPARA | |
| SCHEMBL27577857 | 0.85 | SLC6A4 (0.60) | LDHASLC6A4ACACBCYP1A2CYP2D6 | |
| SCHEMBL10823754 | 0.84 | LDHA (0.61) | LDHASLC6A4ACACBALDH1A1PPARG | |
| SCHEMBL6454761 | 0.84 | LDHA (0.61) | LDHASLC6A4ACACBALDH1A1PPARG | |
| SCHEMBL933857 | 0.84 | LDHA (0.61) | LDHASLC6A4ACACBALDH1A1PPARG | |
| SCHEMBL13623718 | 0.84 | LDHA (0.61) | LDHASLC6A4ACACBALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649184-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2020-05-13 | — | — | EP | claimed |
| EP-3649183-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2020-05-13 | — | — | EP | claimed |
| US-20190010427-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2019-01-10 | — | — | US | claimed |
| US-20190010293-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2019-01-10 | — | — | US | claimed |
| WO-2019010263-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-01-10 | — | — | WO | claimed |
| WO-2019010265-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-01-10 | — | — | WO | claimed |
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| EP-1773794-A4 | AN IMPROVED PROCESS FOR PREPARING N-HYDROXY-4-[5- [4- (5-ISOPROPYL-2-METHYL-l, 3-THIAZOL-4-YL) -PHENOXY] -PENTOXY]-BENZAMIDINE | DONG WHA PHARM IND CO LTD (KR) | 2009-09-09 | — | — | EP | claimed |
| EP-1773794-A1 | AN IMPROVED PROCESS FOR PREPARING N-HYDROXY-4-[5- [4- (5-ISOPROPYL-2-METHYL-l, 3-THIAZOL-4-YL) -PHENOXY] -PENTOXY]-BENZAMIDINE | DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD. (KR) | 2007-04-18 | — | — | EP | claimed |
| WO-2006004368-A1 | AN IMPROVED PROCESS FOR PREPARING N-HYDROXY-4-{5- [4- (5-ISOPROPYL-2-METHYL-l, 3-THIAZOL-4-YL) -PHENOXY] -PENTOXY }-BENZAMIDINE | DONG WHA PHARMACEUTICAL. IND. CO., LTD. (KR) | 2006-01-12 | — | — | WO | claimed |
| EP-4271696-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | Alnylam Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230203098-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | JCR PHARMACEUTICALS CO., LTD. (JP) | 2023-06-29 | — | — | US | disclosed |
| WO-2022147214-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| EP-3694856-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-08-19 | — | — | EP | disclosed |
| EP-3649184-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2020-05-13 | — | — | EP | disclosed |
| US-20190010427-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2019-01-10 | — | — | US | disclosed |
| WO-2019010265-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-01-10 | — | — | WO | disclosed |
| US-20190010293-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2019-01-10 | — | — | US | disclosed |
| WO-2018219356-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-12-06 | — | — | WO | disclosed |
| EP-0426804-A1 | 2-(2-HYDROXY-3-PHENOXYPROPYLAMINO)-ETHOXYBENZENE DERIVATIVES. | ICI PLC (GB) | 1991-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203098-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | TFRC, SLC3A2, SLC7A1 | LDHA 3526/4885SLC6A4 56/4885ACACB 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.